ArticleJournal of neurology2026
Longitudinal spinal cord MRI in adult 5q-SMA: biomarker and pathophysiological insights.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSpinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by biallelic SMN1 mutations and widespread lower motor neuron degeneration. Objective biomarkers to monitor progression and treatment response are critically needed. Spinal cord (SC) MRI, including diffusion tensor imaging (DTI), is a promising non-invasive approach, but data in adults remain scarce.
methodsWe conducted an exploratory longitudinal study in 26 adults with 5q-SMA (type 2: n = 4; type 3: n = 22; median age 29.5 years) and 27 controls undergoing 3 T cervical SC MRI. Gray matter (GM) and total cross-sectional area (CSA) and DTI metrics (FA, MD, AD, RD) were extracted from three white matter tracts. Patients underwent motor (MFM-32, HFMSE, RULM), neurophysiological (CMAP, MUNIX) and fatigue assessments. 22 patients completed 12-14-month follow-up.
resultsTotal SC CSA was reduced across C2-C6 (Cohen d up to 1.02) but showed limited functional correlations. GM CSA was reduced in SMA versus controls (11.90 ± 2.56 vs. 13.92 ± 1.72 mm
conclusionsSelective GM CSA yields robust functional correlations, supporting its role as a candidate imaging biomarker and outperforming total CSA. DTI abnormalities in sensory tracts extend the known pathological scope of adult SMA beyond motor neurons. Longer follow-up is warranted to detect disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.